Preliminary aggregate safety and immunogenicity results from three trials of a purified inactivated Zika virus vaccine candidate: phase 1, randomised, double-blind, placebo-controlled clinical trials

Kayvon Modjarrad, Leyi Lin, Sarah L. George, Kathryn E. Stephenson, Kenneth H. Eckels, Rafael A. De La Barrera, Richard G. Jarman, Erica Sondergaard, Janice Tennant, Jessica L. Ansel, Kristin Mills, Michael Koren, Merlin L. Robb, Jill Barrett, Jason Thompson, Alison E. Kosel, Peter Dawson, Andrew Hale, C. Sabrina Tan, Stephen R. WalshKeith E. Meyer, James Brien, Trevor A. Crowell, Azra Blazevic, Karla Mosby, Rafael A. Larocca, Peter Abbink, Michael Boyd, Christine A. Bricault, Michael S. Seaman, Anne Basil, Melissa Walsh, Veronica Tonwe, Daniel F. Hoft, Stephen J. Thomas, Dan H. Barouch, Nelson L. Michael*

*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

168 Scopus citations

Fingerprint

Dive into the research topics of 'Preliminary aggregate safety and immunogenicity results from three trials of a purified inactivated Zika virus vaccine candidate: phase 1, randomised, double-blind, placebo-controlled clinical trials'. Together they form a unique fingerprint.

Medicine & Life Sciences